目的:评价皮质激素联合环孢素对比皮质激素单用防治穿透性角膜移植(PKP)术后排斥反应的疗效。方法:计算机检索PubMed,EMBASE.com,SCI,Cochrane图书馆,CBM,CNKI数据库,纳入皮质激素联用环孢素对比皮质激素单用防治PKP术后排斥反应的随机对照试验,进行方法学质量评价并应用RevMan软件进行meta分析。结果:共纳入5篇报道,1篇A级文献,B、C级各2篇。Meta结果:术后排斥反应发生情况组间差异有统计学意义(RR=0.3,95%CI 0.140.65);对既发排斥反应的逆转,组间差异无统计学意义(RR=1.15,95%CI 0.93-1.42)。结论:基于当前证据,皮质激素联合环孢素防治PKP术后排斥反应疗效并不优于皮质激素单用。
Citation:
WU Bin,SU Na,CHENG Kai,et al.. Corticosteroids Combined With Cyclosporine for Penetrating Keratoplasty Recipients: A MetaAnalysis. West China Medical Journal, 2009, 24(6): 1365-1368. doi:
Copy
Copyright © the editorial department of West China Medical Journal of West China Medical Publisher. All rights reserved
1. |
WILLIAMS K A, LOWE M T, BARLETT C M, et al. Report from the Australian Corneal Graft Registry[M]. Flinders University Press,2007.
|
2. |
MAUREEN G M, WALTER J S, JOHN D G, et al. Risk factors for corneal graft failure and rejection in the collaborative corneal transplantation studies [J]. Ophthalmology,1994,101:15361547.
|
3. |
JUNI P, ALTMAN D G, EGER M. Assessing the quality of controlled clinical trials [J]. BMJ,2001,323:42-46.
|
4. |
HIGGINS J P T, THOMPSON S G. Quantifying heterogeneity in a metaanalysis [J]. Stat Med,2002,21(11):1539-1558.
|
5. |
UNAL M, YUCEL I. Evaluation of topical ciclosporin 005% for prevention of rejection in highrisk corneal grafts [J]. Br J Ophthalmol,2008,92(10):1411-1414.
|
6. |
POON A, CONSTANTINOU M, LAMOUREUX E, et al. Topical Cyclosporin A in the treatment of acute graft rejection: a randomized controlled trial [J]. Clin Experiment Ophthalmol,2008,36(5):415-421..
|
7. |
NEJABAT M, KHOSHGHADAM J, EGHTEDARI M, et al. Topical cyclosporine A in corneal graft rejection [J]. Am J Immunol,2006,2(2):29-34.
|
8. |
席兴华,秦波,姜德咏,等.环孢霉素A和地塞米松防治穿透性角膜移植术后排斥反应的临床观察[J].中南大学学报,2003,28(6):627-630.
|
9. |
贺焱,孙秉基,李玉淳,等.环孢霉素A滴眼预防高危角膜移植免疫排斥的效果[J].眼外伤职业眼病杂志,1999,21(5):420-421.
|
10. |
HILL J C. Systemic cyclosporine in highrisk keratoplasty: longterm results[J]. Eye,1995,9(Pt4):422-428.
|
- 1. WILLIAMS K A, LOWE M T, BARLETT C M, et al. Report from the Australian Corneal Graft Registry[M]. Flinders University Press,2007.
- 2. MAUREEN G M, WALTER J S, JOHN D G, et al. Risk factors for corneal graft failure and rejection in the collaborative corneal transplantation studies [J]. Ophthalmology,1994,101:15361547.
- 3. JUNI P, ALTMAN D G, EGER M. Assessing the quality of controlled clinical trials [J]. BMJ,2001,323:42-46.
- 4. HIGGINS J P T, THOMPSON S G. Quantifying heterogeneity in a metaanalysis [J]. Stat Med,2002,21(11):1539-1558.
- 5. UNAL M, YUCEL I. Evaluation of topical ciclosporin 005% for prevention of rejection in highrisk corneal grafts [J]. Br J Ophthalmol,2008,92(10):1411-1414.
- 6. POON A, CONSTANTINOU M, LAMOUREUX E, et al. Topical Cyclosporin A in the treatment of acute graft rejection: a randomized controlled trial [J]. Clin Experiment Ophthalmol,2008,36(5):415-421..
- 7. NEJABAT M, KHOSHGHADAM J, EGHTEDARI M, et al. Topical cyclosporine A in corneal graft rejection [J]. Am J Immunol,2006,2(2):29-34.
- 8. 席兴华,秦波,姜德咏,等.环孢霉素A和地塞米松防治穿透性角膜移植术后排斥反应的临床观察[J].中南大学学报,2003,28(6):627-630.
- 9. 贺焱,孙秉基,李玉淳,等.环孢霉素A滴眼预防高危角膜移植免疫排斥的效果[J].眼外伤职业眼病杂志,1999,21(5):420-421.
- 10. HILL J C. Systemic cyclosporine in highrisk keratoplasty: longterm results[J]. Eye,1995,9(Pt4):422-428.